https://doi.org/10.55788/675f3ee0
The phase 3 GEMSTONE-301 trial (NCT03728556) compared the efficacy of the PD-L1 inhibitor sugemalimab (n=255) with placebo (n=126) in patients with stage III, unresectable NSCLC who did not progress after either concurrent or sequential chemoradiotherapy (CRT). Sugemalimab displayed a significant PFS benefit over placebo in the pre-planned interim PFS analysis [2]. At the WCLC 2022, Prof. Yi-Long Wu (Guangdong Provincial People’s Hospital, China) presented the results of the final PFS analysis of this trial.
After a median follow-up of 27.1 months, the median PFS was significantly higher in patients who were treated with sugemalimab versus those treated with placebo (10.5 vs 6.2 months; HR 0.65; 95% CI 0.50–0.84; P=0.0012). In addition, the 3-year PFS rate was 26.1% in the experimental arm and 0% in the placebo arm. These results were consistent in patients who had received sequential CRT (8.1 vs 4.1 months; HR 0.57; 95% CI 0.38–0.87) and in those who were treated with concurrent CRT (15.7 vs 8.3 months; HR 0.71; 95% CI 0.50–1.00). Although the overall survival (OS) data were immature at the time of the analysis, they appear to favour sugemalimab over placebo (median OS not reached vs 25.9 months; HR 0.69; 95% CI 0.49–0.97). No new safety issues were reported in this final PFS analysis.
- Wu Y-L, et al. Sugemalimab vs placebo after cCRT or sCRT in pts with unresectable stage III NSCLC: final PFS analysis of a phase 3 study. OA02.05, WCLC 2022, Vienna, Austria, 06–09 August.
- Zhou Q, et al. Lancet Oncology. 2022;23(2):209-219
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC Next Article
Causal link between haematopoietic loss of Y chromosome and cardiac disease unravelled »
« First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC Next Article
Causal link between haematopoietic loss of Y chromosome and cardiac disease unravelled »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Related Articles

June 25, 2019
I-O monotherapy
September 21, 2021
Genomic profiling of NSCLC may be predictive of immunotherapy response
November 21, 2018
Entrectinib treatment in patients with ROS1+ NSCLC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com